Daniel W. Lin, MD Dr. Lin is Professor and Chief of Urologic Oncology in the Department of Urology, the Director of the Institute for Prostate Cancer Research, and holds the Pritt Family Endowed Chair in Prostate Cancer Research at the University of Washington School of Medicine. Dr. Lin received his undergraduate degree from Stanford University and his medical degree from Vanderbilt University. He completed his urology residency at the University of Washington and urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center, followed by an American Foundation for Urologic Disease (AFUD) Physician Scholar Award at the Fred Hutchinson Cancer Research Center. Dr. Lin serves on various national committees including the guideline panels for the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA). Dr. Lin was Chair of the Male Genital Panel for the American Joint Commission on Cancer (AJCC) 8th Edition. Dr. Lin is co-Chair of the Prostate Cancer Task Force of the NCI GU Steering Committee and is Chair of the Localized Prostate Cancer Committee for the Southwest Oncology Group (SWOG). Dr. Lin is on the Board of Directors for the Society of Urologic Oncology (SUO) and the SUO Clinical Trials Consortium (SUO-CTC), currently the Treasurer of the SUO. Dr. Lin’s major basic/translational research interests are in molecular/genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and novel strategies in high-risk prostate cancer. Dr. Lin is the lead PI for the Canary Prostate Active Surveillance Study (PASS) since its inception in 2008. Dr. Lin is also co-PI of the Pacific Northwest Prostate Cancer Specialized Program of Research Excellence (SPORE) and co-Lead of the Prostate Program at the Fred Hutchinson Cancer Research Center. Dr. Lin receives funding from multiple peer-reviewed grants from the National Cancer Institute (NCI) and Department of Defense (DOD).